{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:06:02Z","timestamp":1790643962203,"version":"4.1.0"},"reference-count":208,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Previous reviews of ceftazidime\/avibactam have focused on in vitro molecular enzymology and microbiology or the clinically associated properties of the combination. Here we take a different approach. We initiate a series of linked reviews that analyse research on the combination that built the primary pharmacology data required to support the clinical and business risk decisions to perform randomized controlled Phase 3 clinical trials, and the additional microbiological research that was added to the above, and the safety and chemical manufacturing and controls data, that constituted successful regulatory licensing applications for ceftazidime\/avibactam in multiple countries, including the USA and the EU. The aim of the series is to provide both a source of reference for clinicians and microbiologists to be able to use ceftazidime\/avibactam to its best advantage for patients, but also a case study of bringing a novel \u03b2-lactamase inhibitor (in combination with an established \u03b2-lactam) through the microbiological aspects of clinical development and regulatory applications, updated finally with a review of resistance occurring in patients under treatment. This first article reviews the biochemistry, structural biology and basic microbiology of the combination, showing that avibactam inhibits the great majority of serine-dependent \u03b2-lactamases in Enterobacterales and Pseudomonas aeruginosa to restore the in vitro antibacterial activity of ceftazidime. Translation to efficacy against infections in vivo is reviewed in the second co-published article, Nichols et al. (J Antimicrob Chemother 2022; 77: 2341\u201352).<\/jats:p>","DOI":"10.1093\/jac\/dkac171","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T11:05:03Z","timestamp":1654340703000},"page":"2321-2340","source":"Crossref","is-referenced-by-count":7,"title":["The primary pharmacology of ceftazidime\/avibactam: <i>in vitro<\/i> translational biology"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-6388","authenticated-orcid":false,"given":"Wright W","family":"Nichols","sequence":"first","affiliation":[{"name":"Didsbury , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A","family":"Bradford","sequence":"additional","affiliation":[{"name":"Nyack, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita D","family":"Lahiri","sequence":"additional","affiliation":[{"name":"Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G","family":"Stone","sequence":"additional","affiliation":[{"name":"Pfizer , Groton, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"2022082518384864700_dkac171-B1","author":"FDA","year":"2019"},{"key":"2022082518384864700_dkac171-B2","author":"EMA","year":"2021"},{"key":"2022082518384864700_dkac171-B3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): a potent new class of non-\u03b2-lactam \u03b2-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr Op Microbiol"},{"key":"2022082518384864700_dkac171-B4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"2022082518384864700_dkac171-B5","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4155\/fmc-2016-0078","article-title":"The road to avibactam: the first clinically useful non-\u03b2-lactam working somewhat like a \u03b2-lactam","volume":"8","author":"Wang","year":"2016","journal-title":"Future Med Chem"},{"key":"2022082518384864700_dkac171-B6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The \u03b2-lactams strike back: ceftazidime-avibactam","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacother"},{"key":"2022082518384864700_dkac171-B7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s15010-017-1096-y","article-title":"Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review","volume":"46","author":"Tuon","year":"2018","journal-title":"Infection"},{"key":"2022082518384864700_dkac171-B8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2022082518384864700_dkac171-B9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s12223-021-00918-5","article-title":"Ceftazidime-avibactam: are we safe from class A carbapenemase producers\u2019 infections?","volume":"66","author":"Moreira","year":"2021","journal-title":"Folia Microbiol (Praha)"},{"key":"2022082518384864700_dkac171-B10","article-title":"Epidemiology and mechanisms of ceftazidime\u2013avibactam resistance in Gram-negative bacteria","author":"Xu","year":"2021","journal-title":"Engineering"},{"key":"2022082518384864700_dkac171-B11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CE.S40698","article-title":"Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections","volume":"9","author":"Lagac\u00e9-Wiens","year":"2014","journal-title":"Core Evid"},{"key":"2022082518384864700_dkac171-B12","author":"Cerexa, Anti-Infective Drugs Advisory Committee"},{"key":"2022082518384864700_dkac171-B13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1586\/14787210.2016.1173542","article-title":"Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections","volume":"14","author":"Gardiner","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2022082518384864700_dkac171-B14","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dkw239","article-title":"Spotlight on ceftazidime\/avibactam: a new option for MDR Gram-negative infections","volume":"71","author":"Falcone","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clinthera.2016.01.018","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination for the treatment of resistant Gram-negative organisms","volume":"38","author":"Sharma","year":"2016","journal-title":"Clin Ther"},{"key":"2022082518384864700_dkac171-B16","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/jac\/dky124","article-title":"Efficacy and safety of ceftazidime\/avibactam: a systematic review and meta-analysis","volume":"73","author":"Sternbach","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B17","doi-asserted-by":"crossref","first-page":"e01052-20","DOI":"10.1128\/AAC.01052-20","article-title":"Is ceftazidime\/avibactam an option for serious infections due to extended-spectrum-\u03b2-lactamase- and AmpC-producing Enterobacterales?: a systematic review and meta-analysis","volume":"65","author":"Isler","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jgar.2021.04.001","article-title":"Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies","volume":"25","author":"Di Bella","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2022082518384864700_dkac171-B19","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-avibactam for the treatment of serious Gram-negative infections with limited treatment options: a systematic literature review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2022082518384864700_dkac171-B20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/antibiotics10091126","article-title":"Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa","volume":"10","author":"Daikos","year":"2021","journal-title":"Antibiotics"},{"key":"2022082518384864700_dkac171-B21","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/CMR.00033-13","article-title":"Investigational antimicrobial agents of 2013","volume":"26","author":"Pucci","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2022082518384864700_dkac171-B22","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.00826-13","article-title":"New \u03b2-lactamase inhibitors: a therapeutic renaissance in an MDR world","volume":"58","author":"Drawz","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd4666","article-title":"A \u03b2-lactamase inhibitor revival provides new hope for old antibiotics","volume":"14","author":"Garber","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2022082518384864700_dkac171-B24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.idc.2016.02.007","article-title":"New \u03b2-lactamase inhibitors in the clinic","volume":"30","author":"Papp-Wallace","year":"2016","journal-title":"Infect Dis Clin N Am"},{"key":"2022082518384864700_dkac171-B25","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2147\/TCRM.S120811","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam for the treatment of complicated intra-abdominal infections","volume":"12","author":"Goodlet","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"2022082518384864700_dkac171-B26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/phar.2210","article-title":"Pharmacokinetics and pharmacodynamics of \u03b2-lactamase inhibitors","volume":"39","author":"Crass","year":"2019","journal-title":"Pharmacother"},{"key":"2022082518384864700_dkac171-B27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.idc.2020.05.001","article-title":"Resistance to novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations: the \u2018price of progress\u2019","volume":"34","author":"Papp-Wallace","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"2022082518384864700_dkac171-B28","doi-asserted-by":"crossref","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2022082518384864700_dkac171-B29","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/14787210.2021.1924674","article-title":"Multidrug-resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"19","author":"Galani","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2022082518384864700_dkac171-B30","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022082518384864700_dkac171-B31","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022082518384864700_dkac171-B32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022082518384864700_dkac171-B33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2022082518384864700_dkac171-B34","doi-asserted-by":"crossref","first-page":"ofz149","DOI":"10.1093\/ofid\/ofz149","article-title":"Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): analyses per US FDA\u2013specified end points","volume":"6","author":"Torres","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2022082518384864700_dkac171-B35","doi-asserted-by":"crossref","first-page":"341ps12","DOI":"10.1126\/scitranslmed.aaf5027","article-title":"2016. What does research reproducibility mean?","volume":"8","author":"Goodman","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022082518384864700_dkac171-B36","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkac172","article-title":"The primary pharmacology of ceftazidime-avibactam: in vivo translational biology and pharmacokinetics\/pharmacodynamics (PK\/PD)","volume":"77","author":"Nichols","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B37","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1128\/AAC.04146-14","article-title":"In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays","volume":"59","author":"Berkhout","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1128\/AAC.01585-15","article-title":"The role of the outer membrane and porins in the susceptibility of \u03b2-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam","volume":"60","author":"Pag\u00e8s","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B39","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1128\/AAC.01722-10","article-title":"Activity of NXL104 in combination with \u03b2-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended spectrum \u03b2-lactamases and class C \u03b2-lactamases","volume":"55","author":"Lagac\u00e9-Wiens","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B40","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1128\/AAC.01696-10","article-title":"In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study)","volume":"55","author":"Walkty","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B41","first-page":"616","article-title":"Third-generation cephalosporins: a review","volume":"14","author":"Cunha","year":"1992","journal-title":"Clin Ther"},{"key":"2022082518384864700_dkac171-B42","author":"EMA","year":"2019"},{"key":"2022082518384864700_dkac171-B43","author":"FDA","year":"2014"},{"key":"2022082518384864700_dkac171-B44","author":"EUCAST","year":"2010"},{"key":"2022082518384864700_dkac171-B45","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1128\/MMBR.69.4.585-607.2005","article-title":"Bacterial cell wall synthesis: new insights from localization studies","volume":"69","author":"Scheffers","year":"2005","journal-title":"Microbiol Mol Biol Rev"},{"key":"2022082518384864700_dkac171-B46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13613-015-0061-0","article-title":"Mechanisms of antimicrobial resistance in Gram-negative bacilli","volume":"5","author":"Rupp\u00e9","year":"2015","journal-title":"Ann Intensive Care"},{"key":"2022082518384864700_dkac171-B47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jac\/17.1.51","article-title":"Inducible type I \u03b2-lactamases of Gram-negative bacteria and resistance to \u03b2-lactam antibiotics","volume":"17","author":"Curtis","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B48","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1128\/AAC.32.9.1443","article-title":"Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime","volume":"32","author":"Fung-Tomc","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B49","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/infdis\/155.4.775","article-title":"\u03b2-Lactamase lability and inducer power of newer \u03b2-lactam antibiotics in relation to their activity against \u03b2-lactamase-inducibility mutants of Pseudomonas aeruginosa","volume":"155","author":"Livermore","year":"1987","journal-title":"J Infect Dis"},{"key":"2022082518384864700_dkac171-B50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0732-8893(97)00064-3","article-title":"Inducible AmpC \u03b2-lactamase producing Gram-negative bacilli from bloodstream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE)","volume":"28","author":"Pfaller","year":"1997","journal-title":"Diagn Microbiol Infec Dis"},{"key":"2022082518384864700_dkac171-B51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1128\/AAC.43.4.769","article-title":"Cloning, sequence analyses, expression, and distribution of ampC-ampR from Morganella morganii clinical isolates","volume":"43","author":"Poirel","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B52","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1128\/AAC.00060-10","article-title":"Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole","volume":"54","author":"Queenan","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B53","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev.mi.41.100187.003041","article-title":"Chromosomal cephalosporinases responsible for multiple resistance to newer \u03b2-lactam antibiotics","volume":"41","author":"Sanders","year":"1987","journal-title":"Annu Rev Microbiol"},{"key":"2022082518384864700_dkac171-B54","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum \u03b2-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"2022082518384864700_dkac171-B55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/1040841X.2013.875515","article-title":"Colonization and infection with extended spectrum \u03b2-lactamase producing Enterobacteriaceae in high-risk patients - review of the literature from a clinical perspective","volume":"42","author":"Biehl","year":"2010","journal-title":"Crit Rev Microbiol"},{"key":"2022082518384864700_dkac171-B56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jgar.2013.01.005","article-title":"Carbapenemases: partners in crime","volume":"1","author":"Bush","year":"2013","journal-title":"J Glob Antimicrob Res"},{"key":"2022082518384864700_dkac171-B57","first-page":"625170","article-title":"ESBLs, a clear and present danger?","volume":"2012","author":"Dhillon","year":"2012","journal-title":"Crit Care Res Pract"},{"key":"2022082518384864700_dkac171-B58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1473-3099(09)70054-4","article-title":"The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria","volume":"9","author":"Nordmann","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2022082518384864700_dkac171-B59","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2022082518384864700_dkac171-B60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"2022082518384864700_dkac171-B61","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2217\/17460913.2.5.501","article-title":"Carbapenemases: molecular diversity and clinical consequences","volume":"2","author":"Poirel","year":"2007","journal-title":"Future Microbiology"},{"key":"2022082518384864700_dkac171-B62","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/jac\/dks121","article-title":"OXA-48-like carbapenemases: the phantom menace","volume":"67","author":"Poirel","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B63","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.01896-13","article-title":"Contemporary diversity of \u03b2-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent \u03b2-lactamase groups","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B64","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009\u201311 in 14 European and Mediterranean countries","volume":"69","author":"Castanheira","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B65","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","article-title":"Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study","volume":"10","author":"Kumarasamy","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2022082518384864700_dkac171-B66","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of \u03b2-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B67","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jac\/dki155","article-title":"Is it necessary to change the classification of \u03b2-lactamases?","volume":"55","author":"Fr\u00e8re","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B68","first-page":"1510","article-title":"AmpC \u03b2-lactamases","volume":"52","author":"Jacoby","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B69","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1021\/ar300327a","article-title":"Class D \u03b2-lactamases: a reappraisal after five decades","volume":"46","author":"Leonard","year":"2013","journal-title":"Acc Chem Res"},{"key":"2022082518384864700_dkac171-B70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/CMR.00019-15","article-title":"A structure-based classification of class A \u03b2-lactamases, a broadly diverse family of enzymes","volume":"29","author":"Philippon","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2022082518384864700_dkac171-B71","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/jac\/dkaa513","article-title":"Class D \u03b2-lactamases","volume":"76","author":"Yoon","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B72","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.39.6.1211","article-title":"A functional classification scheme for \u03b2-lactamases and its correlation with molecular structure","volume":"39","author":"Bush","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B73","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1128\/AAC.50.4.1123-1129.2006","article-title":"\u03b2-Lactamase nomenclature","volume":"50","author":"Jacoby","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B74","doi-asserted-by":"crossref","first-page":"e00564-19","DOI":"10.1128\/AAC.00564-19","article-title":"Molecular basis of class A \u03b2-lactamase inhibition by relebactam","volume":"63","author":"Tooke","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B75","doi-asserted-by":"crossref","first-page":"e01935-19","DOI":"10.1128\/AAC.01935-19","article-title":"Biochemical activity of vaborbactam","volume":"64","author":"Tsivkovski","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev.mi.45.100191.000345","article-title":"Serine \u03b2-lactamases and penicillin-binding proteins","volume":"45","author":"Ghuysen","year":"1991","journal-title":"Annu Rev Microbiol"},{"key":"2022082518384864700_dkac171-B77","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/bj2760269","article-title":"A standard numbering scheme for the class A \u03b2-lactamases","volume":"276","author":"Ambler","year":"1991","journal-title":"Biochem J"},{"key":"2022082518384864700_dkac171-B78","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent reversible non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022082518384864700_dkac171-B79","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against Class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"2022082518384864700_dkac171-B80","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.02247-12","article-title":"Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC \u03b2-lactamases","volume":"57","author":"Lahiri","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B81","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/cb500703p","article-title":"Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48","volume":"10","author":"Lahiri","year":"2015","journal-title":"ACS Chem Biol"},{"key":"2022082518384864700_dkac171-B82","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/jac\/dkw248","article-title":"Structural and sequence analysis of class A \u03b2-lactamases with respect to avibactam inhibition: impact of \u03a9-loop variations","volume":"71","author":"Lahiri","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B83","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1128\/AAC.00897-16","article-title":"Interaction of avibactam with class B metallo-\u03b2-lactamases","volume":"60","author":"Abboud","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B84","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In vitro susceptibility to ceftazidime-avibactam of carbapenem non-susceptible Enterobacteriaceae collected in the INFORM global surveillance study (2012-2014)","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B85","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B86","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bj2950705","article-title":"Interactions between active-site-serine \u03b2-lactamases and mechanism-based inactivators: a kinetic study and an overview","volume":"295","author":"Matagne","year":"1993","journal-title":"Biochem J"},{"key":"2022082518384864700_dkac171-B87","doi-asserted-by":"crossref","first-page":"26674","DOI":"10.1016\/S0021-9258(19)61429-8","article-title":"Mechanism of inhibition of the class A \u03b2-lactamases PC1 and TEM-1 by tazobactam. Observation of reaction products by electrospray ionization mass spectrometry","volume":"275","author":"Yang","year":"2000","journal-title":"J Biol Chem"},{"key":"2022082518384864700_dkac171-B88","author":"FDA.","year":"2019"},{"key":"2022082518384864700_dkac171-B89","author":"FDA.","year":"2018"},{"key":"2022082518384864700_dkac171-B90","doi-asserted-by":"crossref","first-page":"e01841-19","DOI":"10.1128\/AAC.01841-19","article-title":"A standard numbering scheme for class C \u03b2-lactamases","volume":"64","author":"Mack","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B91","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkh358","article-title":"In vitro activity of AVE1330A, an innovative broad-spectrum non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"54","author":"Bonnefoy","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B92","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dkp197","article-title":"In vitro activity of the \u03b2-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases","volume":"64","author":"Stachyra","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B93","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1128\/AAC.00568-10","article-title":"Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"54","author":"Stachyra","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.01512-08","article-title":"Diversity, epidemiology, and genetics of class D \u03b2-lactamases","volume":"54","author":"Poirel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B95","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1021\/bi300508r","article-title":"NXL104 irreversibly inhibits the \u03b2-lactamase from Mycobacterium tuberculosis","volume":"51","author":"Xu","year":"2012","journal-title":"Biochemistry"},{"key":"2022082518384864700_dkac171-B96","doi-asserted-by":"crossref","first-page":"e0136813","DOI":"10.1371\/journal.pone.0136813","article-title":"Inhibition of Klebsiella \u03b2-lactamases (SHV-1 and KPC-2) by avibactam: a structural study","volume":"10","author":"Krishnan","year":"2015","journal-title":"PLoS One"},{"key":"2022082518384864700_dkac171-B97","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.bpj.2019.03.027","article-title":"Molecular insights on the release of avibactam from the acyl-enzyme complex","volume":"116","author":"Lizana","year":"2019","journal-title":"Biophys J"},{"key":"2022082518384864700_dkac171-B98","doi-asserted-by":"crossref","first-page":"e02073-20","DOI":"10.1128\/AAC.02073-20","article-title":"Structural investigations of the inhibition of Escherichia coli AmpC \u03b2-lactamase by diazabicyclooctanes","volume":"65","author":"Lang","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B99","doi-asserted-by":"crossref","first-page":"e02476-16","DOI":"10.1128\/AAC.02476-16","article-title":"Exploring the landscape of diazabicyclooctane (DBO) inhibition: avibactam inactivation of PER-2 \u03b2-lactamase","volume":"61","author":"Ruggiero","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B100","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jac\/dku510","article-title":"\u03b2-Lactamase inhibition by avibactam in Mycobacterium abscessus","volume":"70","author":"Dubee","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B101","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jac\/dkh140","article-title":"Post-antibiotic and post-\u03b2-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum \u03b2-lactamase-producing Gram-negative bacteria","volume":"53","author":"Lavigne","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B102","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/lam.12592","article-title":"The postantibiotic effect and post-\u03b2-lactamase inhibitor effect of ceftazidime, ceftaroline, and aztreonam in combination with avibactam against target Gram-negative bacteria","volume":"63","author":"Pillar","year":"2016","journal-title":"Lett Appl Microbiol"},{"key":"2022082518384864700_dkac171-B103","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/1120009X.2021.1892365","article-title":"2021. Evaluation of the post-antibiotic effect in vivo for the combination of a \u03b2-lactam antibiotic and a \u03b2-lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections","volume":"33","author":"Berkhout","year":"2021","journal-title":"J Chemother"},{"key":"2022082518384864700_dkac171-B104","doi-asserted-by":"crossref","first-page":"e1004949","DOI":"10.1371\/journal.ppat.1004949","article-title":"Natural variants of the KPC-2 carbapenemase have evolved increased catalytic efficiency for ceftazidime hydrolysis at the cost of enzyme stability","volume":"11","author":"Mehta","year":"2015","journal-title":"PLoS Pathog"},{"key":"2022082518384864700_dkac171-B105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.meegid.2016.10.031","article-title":"Klebsiella pneumoniae bla\n            KPC-3 nosocomial epidemic: Bayesian and evolutionary analysis","volume":"46","author":"Angeletti","year":"2016","journal-title":"Infect Genet Evol"},{"key":"2022082518384864700_dkac171-B106","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.diagmicrobio.2016.03.002","article-title":"Inhibitory activity of avibactam against selected \u03b2-lactamases expressed in an isogenic Escherichia coli strain","volume":"86","author":"Giani","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022082518384864700_dkac171-B107","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1021\/bi500589x","article-title":"Inactivation of TEM-1 by avibactam (NXL-104): insights from quantum mechanics\/molecular mechanics metadynamics simulations","volume":"53","author":"Sgrignani","year":"2014","journal-title":"Biochemistry"},{"key":"2022082518384864700_dkac171-B108","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","article-title":"In vitro activity of avibactam (NXL 104) in combination with \u03b2-lactams against Gram-negative bacteria, including OXA-48 \u03b2-lactamase-producing Klebsiella pneumoniae","volume":"39","author":"Akta\u015f","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 4","key":"2022082518384864700_dkac171-B109","first-page":"S125","article-title":"X-ray crystal structure of the Acinetobacter baumannii OXA-24\/40 class D carbapenemase inhibited by NXL104","volume":"17","author":"Docquier","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2022082518384864700_dkac171-B110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/acsinfecdis.5b00007","article-title":"Molecular mechanism of avibactam mediated \u03b2-lactamase inhibition","volume":"1","author":"King","year":"2015","journal-title":"ACS Infect Dis"},{"key":"2022082518384864700_dkac171-B111","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1073\/pnas.1922203117","article-title":"Mechanism of proton transfer in class A \u03b2-lactamase catalysis and inhibition by avibactam","volume":"117","author":"Pemberton","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"2022082518384864700_dkac171-B112","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1093\/jac\/dkv166","article-title":"OP0595, a new diazabicyclooctane: mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u2018enhancer\u2019","volume":"70","author":"Morinaka","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B113","doi-asserted-by":"crossref","first-page":"e1003155","DOI":"10.1371\/journal.pcbi.1003155","article-title":"Variations within class-A \u03b2-lactamase physiochemical properties reflect evolutionary and environmental patterns, but not antibiotic specificity","volume":"9","author":"Verma","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"2022082518384864700_dkac171-B114","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1128\/AAC.39.12.2593","article-title":"Extended-spectrum and inhibitor-resistant TEM-type \u03b2-lactamases: mutations, specificity, and three-dimensional structure","volume":"39","author":"Knox","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B115","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1128\/AAC.00641-09","article-title":"In vitro activity of NXL104 in combination with \u03b2-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases","volume":"53","author":"Endimiani","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B116","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/AAC.04191-14","article-title":"In vitro susceptibility of characterized \u03b2-lactamase-producing strains tested with avibactam combinations","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B117","doi-asserted-by":"crossref","first-page":"28075","DOI":"10.1074\/jbc.M003802200","article-title":"The high resolution crystal structure for class A \u03b2-lactamase PER-1 reveals the bases for its increase in breadth of activity","volume":"275","author":"Tranier","year":"2000","journal-title":"J Biol Chem"},{"key":"2022082518384864700_dkac171-B118","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1128\/AAC.04405-14","article-title":"Avibactam and inhibitor-resistant SHV \u03b2-lactamases","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B119","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1128\/AAC.04406-14","article-title":"Variants of \u03b2-lactamase KPC-2 that are resistant to inhibition by avibactam","volume":"59","author":"Papp-Wallace","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B120","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1128\/AAC.00047-16","article-title":"Identification of novel VEB \u03b2-lactamase enzymes: impact on avibactam inhibition","volume":"60","author":"Lahiri","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B121","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B122","first-page":"717","article-title":"Analysis of the structure and function of FOX-4 cephamycinase","volume":"59","author":"Lefurgy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B123","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.01410-08","article-title":"Extended-spectrum cephalosporinases in Pseudomonas aeruginosa","volume":"53","author":"Rodr\u00edguez-Mart\u00ednez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B124","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-micro-090110-102911","article-title":"Epidemiological expansion, structural studies, and clinical challenges of new \u03b2-lactamases from gram-negative bacteria","volume":"65","author":"Bush","year":"2011","journal-title":"Annu Rev Microbiol"},{"key":"2022082518384864700_dkac171-B125","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/jac\/dku237","article-title":"Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C \u03b2-lactamase enzyme","volume":"69","author":"Lahiri","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B126","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/s41467-020-15666-2","article-title":"Escape mutations circumvent a tradeoff between resistance to a \u03b2-lactam and resistance to a \u03b2-lactamase inhibitor","volume":"11","author":"Russ","year":"2020","journal-title":"Nat Commun"},{"key":"2022082518384864700_dkac171-B127","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1574-6968.2001.tb10519.x","article-title":"Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate","volume":"195","author":"Barnaud","year":"2001","journal-title":"FEMS Microbiol Lett"},{"key":"2022082518384864700_dkac171-B128","doi-asserted-by":"crossref","first-page":"e00198-20","DOI":"10.1128\/AAC.00198-20","article-title":"Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion","volume":"64","author":"Kawai","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B129","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02286-15","article-title":"Activity of ceftazidime-avibactam against extended-spectrum- and AmpC \u03b2-lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014","volume":"60","author":"Karlowsky","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diagmicrobio.2015.02.003","article-title":"Activities of ceftazidime, ceftaroline and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single \u03b2-lactamases","volume":"82","author":"Papp-Wallace","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022082518384864700_dkac171-B131","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B132","doi-asserted-by":"crossref","first-page":"e01816-19","DOI":"10.1128\/AAC.01816-19","article-title":"Ceftazidime-avibactam resistance associated with increased blaKPC-3 gene copy number mediated by pKpQIL plasmid derivatives in sequence type 258 Klebsiella pneumoniae","volume":"64","author":"Coppi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B133","first-page":"3336","article-title":"Selection of mutants with resistance or diminished susceptibility to ceftazidime\/avibactam from ESBL- and AmpC-producing Enterobacteriaceae","volume":"73","author":"Livermore","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B134","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00257-10","article-title":"Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to \u03b2-lactam antibiotics","volume":"54","author":"Alvarez-Ortega","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B135","doi-asserted-by":"crossref","first-page":"e02534-16","DOI":"10.1128\/AAC.02534-16","article-title":"Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum \u03b2-lactamases","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B136","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.tim.2018.06.007","article-title":"Evolution of plasmid-mediated antibiotic resistance in the clinical context","volume":"26","author":"San Millan","year":"2018","journal-title":"Trends Microbiol"},{"key":"2022082518384864700_dkac171-B137","doi-asserted-by":"crossref","first-page":"e00451-17","DOI":"10.1128\/AAC.00451-17","article-title":"Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the \u03b2-lactamase KPC-2","volume":"61","author":"Compain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B138","doi-asserted-by":"crossref","first-page":"e00357-18","DOI":"10.1128\/AAC.00357-18","article-title":"Combination of amino acid substitutions leading to CTX-M-15-mediated resistance to the ceftazidime-avibactam combination","volume":"62","author":"Compain","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B139","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.02102-15","article-title":"Distinctive binding of avibactam to penicillin-binding proteins of Gram-negative and Gram-positive bacteria","volume":"60","author":"Asli","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B140","doi-asserted-by":"crossref","first-page":"e00282-18","DOI":"10.1128\/AAC.00282-18","article-title":"First penicillin-binding protein occupancy patterns of \u03b2-lactams and \u03b2-lactamase inhibitors in Klebsiella pneumoniae","volume":"62","author":"Sutaria","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B141","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF02185845","article-title":"In vitro activity of combinations of \u03b2-lactamase antibiotics with \u03b2-lactamase inhibitors against cephalosporinase-producing bacteria","volume":"8","author":"Kitzis","year":"1989","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022082518384864700_dkac171-B142","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/IDR.S53874","article-title":"The \u03b2-lactamase inhibitor avibactam (NXL104) does not induce ampC \u03b2-lactamase in Enterobacter cloacae","volume":"6","author":"Miossec","year":"2013","journal-title":"Infect Drug Resist"},{"key":"2022082518384864700_dkac171-B143","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1093\/jac\/dkx298","article-title":"AmpC \u03b2-lactamase induction by avibactam and relebactam","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B144","doi-asserted-by":"crossref","first-page":"e02187-18","DOI":"10.1128\/AAC.02187-18","article-title":"Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections and nosocomial pneumonia","volume":"63","author":"Das","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B145","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.3390\/ijms22063051","article-title":"Molecular basis of AmpC \u03b2-lactamase induction by avibactam in Pseudomonas aeruginosa: PBP occupancy, live cell binding dynamics and impact on resistant clinical isolates harboring PDC-X variants","volume":"22","author":"L\u00f3pez-Arg\u00fcello","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2022082518384864700_dkac171-B146","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jac\/22.3.275","article-title":"Towards a fundamental understanding of the MIC of \u03b2-lactam antibiotics","volume":"22","author":"Nichols","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B147","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/jac\/dkn320","article-title":"NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum \u03b2 lactamases and carbapenemases","volume":"62","author":"Livermore","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B148","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/jac\/dkv094","article-title":"Activity of ceftazidime\/avibactam against isogenic strains of Escherichia coli containing KPC and SHV \u03b2-lactamases with single amino acid substitutions in the \u03a9-loop","volume":"70","author":"Winkler","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B149","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1093\/jac\/dkz149","article-title":"ESBLs and resistance to ceftazidime\/avibactam and ceftolozane\/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa","volume":"74","author":"Ortiz de la Rosa","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B150","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime\u200a+\u200aNXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B151","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ijantimicag.2016.12.011","article-title":"The impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam\/\u03b2-lactam combinations","volume":"49","author":"McLeod","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2022082518384864700_dkac171-B152","doi-asserted-by":"crossref","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B153","doi-asserted-by":"crossref","first-page":"e02510-16","DOI":"10.1128\/AAC.02510-16","article-title":"Inhibition by avibactam and clavulanate of the \u03b2-lactamases KPC-2 and CTX-M-15 harboring the substitution N132G in the conserved motif SDN","volume":"61","author":"Ourghanlian","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B154","doi-asserted-by":"crossref","first-page":"e00775-20","DOI":"10.1128\/mSphere.00775-20","article-title":"A ceftazidime-avibactam-resistant and carbapenem-susceptible Klebsiella pneumoniae strain harboring blaKPC-14 isolated in New York City","volume":"5","author":"Niu","year":"2020","journal-title":"mSphere"},{"key":"2022082518384864700_dkac171-B155","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1128\/AAC.02625-14","article-title":"Reclaiming the efficacy of \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime","volume":"58","author":"Papp-Wallace","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B156","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/jac\/dku002","article-title":"Avibactam activity against extended-spectrum AmpC \u03b2-lactamases","volume":"69","author":"Porres-Osante","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B157","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B158","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1128\/AAC.00080-14","article-title":"Activities of ceftazidime and avibactam against \u03b2-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model","volume":"58","author":"Coleman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B159","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jiac.2014.08.028","article-title":"In vitro susceptibility of characterized \u03b2-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations","volume":"21","author":"Yoshizumi","year":"2015","journal-title":"J Infect Chemother"},{"key":"2022082518384864700_dkac171-B160","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1128\/AAC.03579-14","article-title":"Efficacy of a ceftazidime-avibactam combination in a murine model of septicemia caused by Enterobacteriaceae species producing AmpC or extended-spectrum \u03b2-lactamases","volume":"58","author":"Levasseur","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B161","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1128\/AAC.02894-14","article-title":"Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against \u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"58","author":"Keepers","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B162","first-page":"1400","article-title":"Pharmacodynamics of ceftazidime\/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa","volume":"72","author":"Buyck","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B163","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1128\/AAC.01282-16","article-title":"Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant \u03b2-lactamase resistance mechanisms","volume":"60","author":"Torrens","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B164","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1128\/AAC.48.8.3203-3206.2004","article-title":"Role of \u03b2-lactamases and porins in resistance to ertapenem and other \u03b2-lactams in Klebsiella pneumoniae","volume":"48","author":"Jacoby","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B165","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/bit.260440817","article-title":"Biosorption of mercury by the inactivated cells of Pseudomonas aeruginosa PU21 (Rip64)","volume":"44","author":"Chang","year":"1994","journal-title":"Biotechnol Bioeng"},{"key":"2022082518384864700_dkac171-B166","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1128\/AAC.45.9.2598-2603.2001","article-title":"GES-2, a class A \u03b2-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem","volume":"45","author":"Poirel","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B167","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0167-4838(01)00164-9","article-title":"Mutagenesis of amino acid residues in the SHV-1 \u03b2-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance","volume":"1547","author":"Hujer","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"2022082518384864700_dkac171-B168","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1128\/AAC.41.4.838","article-title":"Emergence of an inhibitor-resistant \u03b2-lactamase (SHV-10) derived from an SHV-5 variant","volume":"41","author":"Prinarakis","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B169","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/AAC.49.7.2941-2948.2005","article-title":"Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 \u03b2-lactamase: defining a unique family of class C enzymes","volume":"49","author":"Hujer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B170","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1128\/AAC.01633-05","article-title":"Naturally occurring extended-spectrum cephalosporinases in Escherichia coli","volume":"50","author":"Mammeri","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B171","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/jac\/dkm227","article-title":"Extension of the hydrolysis spectrum of AmpC \u03b2-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix","volume":"60","author":"Mammeri","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B172","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1128\/AAC.01513-10","article-title":"Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum \u03b2-lactamase AmpC","volume":"55","author":"Guillon","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B173","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/bj2280241","article-title":"The \u03b2-lactamase of Enterobacter cloacae P99. Chemical properties, N-terminal sequence and interaction with 6 \u03b2-halogenopenicillanates","volume":"228","author":"Joris","year":"1985","journal-title":"Biochem J"},{"key":"2022082518384864700_dkac171-B174","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1128\/am.23.4.765-769.1972","article-title":"Comparison of the substrate specificities of the \u03b2-lactamases from Klebsiella aerogenes 1082E and Enterobacter cloacae P99","volume":"23","author":"Marshall","year":"1972","journal-title":"Appl Microbiol"},{"key":"2022082518384864700_dkac171-B175","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jac\/dkl154","article-title":"OXA-1 is OXA-30 is OXA-1","volume":"58","author":"Boyd","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B176","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/CMR.00117-13","article-title":"OXA \u03b2-lactamases","volume":"27","author":"Evans","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2022082518384864700_dkac171-B177","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/jac\/dkz209","article-title":"Unravelling ceftazidime\/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity","volume":"74","author":"Oueslati","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B178","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/jac\/dki482","article-title":"OXA-type carbapenemases","volume":"57","author":"Walther-Rasmussen","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B179","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1128\/AAC.45.6.1615-1620.2001","article-title":"Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa","volume":"45","author":"Aubert","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B180","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.00022-11","article-title":"OXA-163, an OXA-48-related class D \u03b2-lactamase with extended activity toward expanded-spectrum cephalosporins","volume":"55","author":"Poirel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B181","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1128\/AAC.41.10.2188","article-title":"OXA-18, a class D clavulanic acid-inhibited extended-spectrum \u03b2-lactamase from Pseudomonas aeruginosa","volume":"41","author":"Philippon","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B182","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam: INFORM 2012-2014","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B183","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/jac\/dkz243","article-title":"Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime\/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals","volume":"74","author":"Castanheira","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B184","doi-asserted-by":"crossref","first-page":"e02590-17","DOI":"10.1128\/AAC.02590-17","article-title":"Ceftazidime-avibactam susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"62","author":"Nichols","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B185","author":"CLSI","year":"2020"},{"key":"2022082518384864700_dkac171-B186","author":"EUCAST"},{"key":"2022082518384864700_dkac171-B187","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/jac\/dku551","article-title":"Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients","volume":"70","author":"Chalhoub","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B188","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1128\/AAC.05136-14","article-title":"Evaluation of the activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa","volume":"59","author":"Pitart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B189","doi-asserted-by":"crossref","first-page":"e02569-17","DOI":"10.1128\/AAC.02569-17","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012 to 2015","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B190","doi-asserted-by":"crossref","first-page":"e01814-18","DOI":"10.1128\/AAC.01814-18","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM global surveillance program, 2012 to 2015","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B191","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkx438","article-title":"Activity of ceftazidime\/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015\u201316","volume":"73","author":"Livermore","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B192","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.01269-15","article-title":"Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection","volume":"60","author":"Berkhout","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B193","doi-asserted-by":"crossref","first-page":"e00592-18","DOI":"10.1128\/AAC.00592-18","article-title":"In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B194","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.gene.2005.05.027","article-title":"Characterization of poxB, a chromosomal-encoded Pseudomonas aeruginosa oxacillinase","volume":"358","author":"Kong","year":"2005","journal-title":"Gene"},{"key":"2022082518384864700_dkac171-B195","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/AAC.48.6.2043-2048.2004","article-title":"Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa","volume":"48","author":"Girlich","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B196","doi-asserted-by":"crossref","first-page":"763.e5","DOI":"10.1016\/j.cmi.2019.03.011","article-title":"Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam","volume":"25","author":"Galani","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2022082518384864700_dkac171-B197","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/jac\/dkt433","article-title":"Dissemination of carbapenemase-producing Enterobacteriaceae in France, 2012","volume":"69","author":"Dortet","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B198","doi-asserted-by":"crossref","first-page":"20549","DOI":"10.2807\/1560-7917.ES2013.18.31.20549","article-title":"Intercontinental spread of OXA-48 \u03b2-lactamase producing Enterobacteriaceae over a 11-year period, 2001 to 2011","volume":"18","author":"Potron","year":"2013","journal-title":"Euro Surveill"},{"key":"2022082518384864700_dkac171-B199","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkv004","article-title":"Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC","volume":"70","author":"Lahiri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384864700_dkac171-B200","doi-asserted-by":"crossref","first-page":"e8842","DOI":"10.1371\/journal.pone.0008842","article-title":"Complete genome sequence of the multiresistant taxonomic outlier Pseudomonas aeruginosa PA7","volume":"5","author":"Roy","year":"2010","journal-title":"PLoS One"},{"key":"2022082518384864700_dkac171-B201","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1128\/AAC.01807-15","article-title":"Characterization of a carbapenem-hydrolyzing enzyme, PoxB, in Pseudomonas aeruginosa PAO1","volume":"60","author":"Zincke","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B202","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/AAC.00163-15","article-title":"Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of \u03b2-lactamase-producing strains","volume":"59","author":"Castanheira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B203","doi-asserted-by":"crossref","first-page":"e01076-18","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B204","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1128\/AAC.02123-13","article-title":"In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B205","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijid.2020.07.050","article-title":"In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula","volume":"99","author":"Sonnevend","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2022082518384864700_dkac171-B206","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(13)70168-3","article-title":"Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study","volume":"13","author":"Edelstein","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2022082518384864700_dkac171-B207","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.02379-15","article-title":"Multiyear, multinational survey of the incidence and global distribution of metallo-\u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384864700_dkac171-B208","author":"FDA","year":"2018"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/9\/2321\/45536591\/dkac171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/9\/2321\/45536591\/dkac171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T18:43:25Z","timestamp":1661453005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/9\/2321\/6601966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":208,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,6,4]]},"published-print":{"date-parts":[[2022,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac171","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,6,4]]}}}